RMi Pre-opening: Weighing the real risks; certainty versus uncertainty

January 26, 2026 6:40am

This week, about rate decision, share pricing raking and earnings reporting

As Q4/25 and FY25 earnings cycle approaches

Pre-open Signals: 3 Negative, 2 Neutral goining red or 1 Positive Indications; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t! 

I make a commitment to provide need-to-know “facts in evidence” as an equity’s volatility is one tactical signal for stocks. My thesis is important in trying to distinguish the temporary from real pricing digression or progress

RMi Closing Bell: Share pricing regenerates … https://www.regmedinvestors.com/articles/14276

RMi Financing Note: AxoGen (AXGN) Completed an offering of 4 M shares at $31.00 … https://www.regmedinvestors.com/articles/14281

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Monday: The pre-open Dow futures are DOWN -0.03% or (-16 points), the S&P futures are DOWN -0.17% or (-11 points) and the Nasdaq futures are DOWN -0.33% or ( -83 points)

• U.S. stock futures are sliding down on Monay. 1/26
• European markets opened positive, then slipped a bit,
• Asia Pacific markets traded mixed

Economic Data: 8:30 am Durable-goods orders (delayed report) - Nov. and Durable-goods minus transportation Nov.                               

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Friday: The Dow closed DOWN -285.30 points or -0.58%, the S&P closed UP +2.26 points or +0.03% while the Nasdaq closed UP +65.225 points or +0.28%
• Thursday: The Dow closed UP +306.78 points or +0.63%, the S&P closed UP +37.73 points or +0.55% while the Nasdaq closed UP +211.195 points or +0.91%
• Wednesday: The Dow closed UP +588.64 points or +1.21%, the S&P closed UP +78.76 points or +1.16% while the Nasdaq closed UP +270.502 points or +1.18%
• Tuesday: The Dow closed DOWN -870.74 points or -1.76%, the S&P closed DOWN -143.15 points or -2.06% while the Nasdaq closed DOWN -561.065 points or -2.39%
• Monday was a market holiday

• Last week: The S&P 500 was down -0.4%, the Dow -0.5% and the Nasdaq was down -0.1%.
• The previous week: The S&P 500 was down -0.4%, the Dow -0.3% and the Nasdaq was down -0.7%.

Q1/26 – Q1 – 2 holiday, 2 neutral, 5 negative and 5 positive closes  

Q4 – December,

• 1 holiday, 8 positive and 12 negative closes
• November, 1 holiday, 8 positive and 11 negative sessions
• October, 1 neutral, 10 positive and 12 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Capricor Therapeutics (CAPR closed down -$0.97 with a negative -$0.19 or -0.82% pre-open

Vertex (VRTX) closed up +$1.06 after Thursday’s +$5.21 after Wednesday’s +$19.06 after Tuesday’s +$0.72 after the previous Friday’s +$2.44 with a neutral % pre-open

AxoGen (AXGN) closed up +$0.83 after Thursday’s -$1.01 with a negative -$0.33 or -1.01% (post-offering) pre-open

Alnylam Pharmaceuticals (ALNY) closed down -$12.02 after Thursday’s +$4.54 after Wednesday’s +$9.93 after Tuesday’s -$3.46 after the previous Friday’s -$0.33 with a neutral pre-open

Moderna (MRNA) closed down -$3.08 after Thursday’s +$2.06 after Wednesday’s +$6.81 after Tuesday’s +$1.16 after the previous Friday’s +$2.48 with a negative -$0.32 or -0.67% pre-open

Sarepta Therapeutics (SRPT) closed down -$0.66 with a positive +$1.04 or +4.92% pre-open

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

• 5 am ploughed and starting to shovel 24 inches, wit 3 layers of clothes

Also, the Q4 and FY25 earnings cycle is about to appear beginning 2/5 and 2 more on 2/14

• 2/5 – Arrowhead Pharmaceuticals (ARWR)
• 2/5 – IQVA Holdings (IQV)
• 2/12 -Vertex (VRTX)

Welcome to my world of defining the “grey’ in our universe!

• I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
• if I wanted to be liked, I wouldn’t have been an analyst/journalist.

January 3^rd Week:

• 1/23 – Friday closed negative with 6 incliners, 33 decliners and 1 flat
• 1/22 – Thursday closed positive with 33 incliners, 6 decliners and 1 flat
• 1/21- 1/21 – Wednesday closed positive with 33 incliners, 6 decliners and 1 flat
• 1/20 - Tuesday closed negative with 16 incliners, 22 decliners and 2 flats
• 1/19 – Monday was a holiday, MLK, Jr Day

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.